Susquehanna Fundamental Investments, LLC Ionis Pharmaceuticals Inc Transaction History

Susquehanna Fundamental Investments, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$30.17 - $34.97 $1.64 Million - $1.9 Million	-54,406 Reduced 25.54%	158,609 $4.79 Million
Q4 2024 Feb 14, 2025	BUY	$33.73 - $40.36 $5.65 Million - $6.76 Million	167,441 Added 367.4%	213,015 $7.45 Million
Q1 2024 May 07, 2024	BUY	$42.03 - $53.55 $1.92 Million - $2.44 Million	45,574 New	45,574 $1.98 Billion
Q1 2023 May 16, 2023	SELL	$33.58 - $41.2 $856,860 - $1.05 Million	-25,517 Reduced 27.31%	67,918 $2.43 Million
Q4 2022 Feb 14, 2023	SELL	$37.12 - $46.52 $2.23 Million - $2.8 Million	-60,201 Reduced 39.18%	93,435 $3.53 Million
Q3 2022 Nov 14, 2022	BUY	$36.54 - $48.66 $5.61 Million - $7.48 Million	153,636 New	153,636 $6.8 Million
Q3 2021 Nov 15, 2021	SELL	$33.54 - $40.55 $2.96 Million - $3.58 Million	-88,273 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$34.54 - $47.25 $1.16 Million - $1.58 Million	33,469 Added 61.07%	88,273 $3.52 Million
Q1 2021 May 17, 2021	BUY	$42.51 - $63.78 $2.33 Million - $3.5 Million	54,804 New	54,804 $2.46 Million

413

149M

1.72M

722K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $9.09B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.